You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy
|
|---|---|
| Published in |
Canadian Medical Association Journal, April 2016
|
| DOI | 10.1503/cmaj.151243 |
| Pubmed ID | |
| Authors |
David Henry, Colin Dormuth, Brandace Winquist, Greg Carney, Shawn Bugden, Gary Teare, Linda E. Lévesque, Anick Bérard, J. Michael Paterson, Robert W. Platt |
| Abstract |
Isotretinoin, a teratogen, is widely used to treat cystic acne. Although the risks of pregnancy during isotretinoin therapy are well recognized, there are doubts about the level of adherence with the pregnancy prevention program in Canada. Our objective was to evaluate the effectiveness of the Canadian pregnancy prevention program in 4 provinces: British Columbia, Saskatchewan, Manitoba and Ontario. Using administrative data, we identified 4 historical cohorts of female users of isotretinoin (aged 12-48 yr) for the period 1996 to 2011. We defined pregnancy using International Statistical Classification of Diseases and billing codes. One definition included only cases with documented pregnancy outcomes (high-specificity definition); the other definition also included individuals recorded as receiving prenatal care (high-sensitivity definition). We studied new courses of isotretinoin and detected pregnancies in 2 time windows: during isotretinoin treatment only and up to 42 weeks after treatment. Live births were followed for 1 year to identify congenital malformations. A total of 59 271 female patients received 102 308 courses of isotretinoin. Between 24.3% and 32.9% of participants received prescriptions for oral contraceptives while they were taking isotretinoin, compared with 28.3% to 35.9% in the 12 months before isotretinoin was started. According to the high-specificity definition of pregnancy, there were 186 pregnancies during isotretinoin treatment (3.1/1000 isotretinoin users), compared with 367 (6.2/1000 users) according to the high-sensitivity definition. By 42 weeks after treatment, there were 1473 pregnancies (24.9/1000 users), according to the high-specificity definition. Of these, 1331 (90.4%) terminated spontaneously or were terminated by medical intervention. Among the 118 live births were 11 (9.3%) cases of congenital malformation. Pregnancy rates during isotretinoin treatment remained constant between 1996 and 2011. Adherence to the isotretinoin pregnancy prevention program in Canada was poor during the 15-year period of this study. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 8 | 67% |
| Spain | 1 | 8% |
| Japan | 1 | 8% |
| Unknown | 2 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 67% |
| Practitioners (doctors, other healthcare professionals) | 2 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
| Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 98 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 16% |
| Student > Master | 11 | 11% |
| Student > Ph. D. Student | 9 | 9% |
| Student > Postgraduate | 8 | 8% |
| Researcher | 7 | 7% |
| Other | 17 | 17% |
| Unknown | 30 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 11% |
| Nursing and Health Professions | 7 | 7% |
| Psychology | 4 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 5 | 5% |
| Unknown | 32 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 72. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2020.
All research outputs
#588,609
of 25,271,884 outputs
Outputs from Canadian Medical Association Journal
#959
of 9,403 outputs
Outputs of similar age
#10,679
of 305,190 outputs
Outputs of similar age from Canadian Medical Association Journal
#14
of 102 outputs
Altmetric has tracked 25,271,884 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,403 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,190 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.